Conditionally replicative adenoviral vectors for malignant glioma

Adam M. Sonabend, Ilya V. Ulasov, Maciej S. Lesniak*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


High-grade gliomas constitute an important challenge to modern medicine, and although great effort has been made to prolong patient survival, the prognosis for this disease remains poor. Due to recent discoveries in the molecular basis of gliomas, gene therapy is becoming a promising alternative. In this review, we discuss the use of conditionally replicative adenoviral vectors (CRAd) and their applications in neuro-oncology. Such vectors, when rendered conditionally replicative via transductional and transcriptional modifications, offer great promise for patients with malignant brain tumours. We review data from preclinical and clinical studies utilising such vectors and discuss the limitations and future perspectives of CRAd oncolytic therapy for malignant glioma.

Original languageEnglish (US)
Pages (from-to)99-115
Number of pages17
JournalReviews in Medical Virology
Issue number2
StatePublished - Mar 1 2006

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases


Dive into the research topics of 'Conditionally replicative adenoviral vectors for malignant glioma'. Together they form a unique fingerprint.

Cite this